Document Detail


Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative tumours of the retina.
MedLine Citation:
PMID:  16547325     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To investigate the safety and efficacy of beta ray brachytherapy in treatment of vasoproliferative tumours of the retina (VTR). METHODS: 35 consecutive patients with symptomatic VTR were treated with a ruthenium-106 ((106)Ru) plaque. Three tumours had been treated previously (two with cryotherapy; one with transpupillary thermotherapy). 32 VTR (91.4%) were located in the lower half of the retina and all of them were found between the mid-periphery and the ora serrata. The mean tumour thickness was 2.8 mm. An exudative retinal detachment was present in 25 eyes (71.4%) and in 15 cases (42.9%) hard exudates were found in the macula. The major symptom was loss of vision (77.1%). RESULTS: Brachytherapy was well tolerated by every patient. The mean applied dose was 416 Gy at the sclera and 108 Gy at the tumour apex. In all but four eyes (88.6%), it was possible to control the VTR activity. The median follow up time was 24 months. Three of the above mentioned four eyes with treatment failure had had secondary glaucoma before therapy. There was no case of radiation induced neuropathy or retinopathy. Cataract surgery was necessary for five patients. The development of epiretinal gliosis was the most common event during follow up (n = 10, 28.6%). The mean visual acuity decreased slightly (0.33 before and 0.29 after brachytherapy). Multivariate analysis showed that the presence of macular pathology before treatment was associated with a 6.1-fold risk of vision of 0.25 or better (p = 0.03). CONCLUSIONS: beta ray brachytherapy with (1106)Ru plaques was able to control the activity of VTR and retain vision. Cases with secondary glaucoma before treatment had a very poor prognosis.
Authors:
G Anastassiou; N Bornfeld; A O Schueler; H Schilling; S Weber; D Fluehs; B Jurklies; O Vij; W Sauerwein
Related Documents :
23416265 - Screening for potential hazard effects from four nitramines on human eye and skin.
23412525 - Iris claw intraocular lens: a viable option in monocular surgical aphakia.
9428935 - An experimental model for infiltration of malignant lymphoma to the eye and brain.
22705275 - Central serous retinal detachment following glaucoma filtration surgery.
8909215 - Long-term follow-up of ocular findings in children with stickler's syndrome.
15204045 - Effect of multi-functional fabric on sleep stages and growth hormone levels during sleep.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The British journal of ophthalmology     Volume:  90     ISSN:  0007-1161     ISO Abbreviation:  Br J Ophthalmol     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-03-20     Completed Date:  2006-04-13     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0421041     Medline TA:  Br J Ophthalmol     Country:  England    
Other Details:
Languages:  eng     Pagination:  447-50     Citation Subset:  IM    
Affiliation:
Augenklinik, Universitätsklinikum Essen, 45122 Essen, Germany. gerasimos.anastassion@uni-essen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Brachytherapy / adverse effects,  methods*
Cataract / etiology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Multivariate Analysis
Neoplasms, Vascular Tissue / pathology,  radiotherapy*
Radiation Injuries / etiology
Retinal Neoplasms / pathology,  radiotherapy*
Ruthenium Radioisotopes / adverse effects,  therapeutic use*
Visual Acuity
Chemical
Reg. No./Substance:
0/Ruthenium Radioisotopes
Comments/Corrections
Comment In:
Br J Ophthalmol. 2006 Apr;90(4):399-400   [PMID:  16547310 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development of atrophy of the retinal pigment epithelium around disciform scars.
Next Document:  Do infants of birth weight less than 1500 g require additional long term ophthalmic follow up?